Marc Yves Romain Henrion

Marc Yves Romain Henrion

Auto-generated profile, based on publicly available information

Marc Yves Romain Henrion

Liverpool School of Tropical Medicine, Liverpool, UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Journal of Hepatology
Verified
Journal Article
Open access
ASAlexander J. Stockdale
Alexander J. Stockdale
BKBenno Kreuels
Benno Kreuels
MHMarc Y.R. Henrion
Marc Y.R. Henrion
EGEmanuele Giorgi
Emanuele Giorgi
IKIrene Kyomuhangi
Irene Kyomuhangi
AGAnna Maria Geretti
Anna Maria Geretti
There are uncertainties about the epidemic patterns of hepatitis delta virus (HDV) infection and its contribution to the burden of liver disease. We estimated the global prevalence of HDV infection and explored its contribution to the development of cirrhosis and hepatocellular carcinoma (HCC) among hepatitis B surface antigen (HBsAg)-positive people. We searched Pubmed, EMBASE and Scopus for studies reporting on total or IgG anti-HDV among HBsAg-positive people. Anti-HDV prevalence was estimated using a binomial mixed model, weighting for study quality and population size. The population attributable fraction (PAF) of HDV to cirrhosis and HCC among HBsAg-positive people was estimated using random-effects models. We included 282 studies, comprising 376 population samples from 95 countries, which together tested 120,293 HBsAg-positive people for anti-HDV. The estimated anti-HDV prevalence was 4.5% (95% CI 3.6, 5.7) among all HBsAg-positive people and 16.4% (14.6, 18.6) among those attending hepatology clinics. Worldwide, 0.16% (0.11, 0.25) of the general population, totalling 12.0 (8.7, 18.7) million people, were estimated to be anti-HDV positive. Prevalence among HBsAg-positive people was highest in Mongolia, the Republic of Moldova and countries in Western and Middle Africa, and was higher in injecting drug users, haemodialysis recipients, men who have sex with men, commercial sex workers, and those with hepatitis C virus or HIV. Among HBsAg-positive people, preliminary PAF estimates of HDV were 18% (10, 26) for cirrhosis and 20% (8, 33) for HCC. An estimated 12 million people worldwide have experienced HDV infection, with higher prevalence in certain geographic areas and populations. HDV is a significant contributor to HBV-associated liver disease. More quality data are needed to improve the precisions of burden estimates.

21 March 2017 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
JTJon B. Toledo
Jon B. Toledo
MAMatthias Arnold
Matthias Arnold
GKGabi Kastenmüller
Gabi Kastenmüller
RCRui Chang
Rui Chang
RBRebecca Baillie
Rebecca Baillie
RKRima Kaddurah‐Daouk
Rima Kaddurah‐Daouk

1 June 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
YWYufei Wang
Yufei Wang
JMJames D McKay
James D McKay
TRThorunn Rafnar
Thorunn Rafnar
ZWZhaoming Wang
Zhaoming Wang
MTMaria N Timofeeva
Maria N Timofeeva
CAChristopher I Amos
Christopher I Amos
Richard Houlston, Maria Teresa Landi and colleagues report the identification of large-effect associations for squamous lung cancer with rare variants in BRCA2 and CHEK2. We conducted imputation to the 1000 Genomes Project of four genome-wide association studies of lung cancer in populations of European ancestry (11,348 cases and 15,861 controls) and genotyped an additional 10,246 cases and 38,295 controls for follow-up. We identified large-effect genome-wide associations for squamous lung cancer with the rare variants BRCA2 p.Lys3326X (rs11571833, odds ratio (OR) = 2.47, P = 4.74 × 10−20) and CHEK2 p.Ile157Thr (rs17879961, OR = 0.38, P = 1.27 × 10−13). We also showed an association between common variation at 3q28 (TP63, rs13314271, OR = 1.13, P = 7.22 × 10−10) and lung adenocarcinoma that had been previously reported only in Asians. These findings provide further evidence for inherited genetic susceptibility to lung cancer and its biological basis. Additionally, our analysis demonstrates that imputation can identify rare disease-causing variants with substantive effects on cancer risk from preexisting genome-wide association study data.

1 April 2017 in Cell Stem Cell
Verified
Journal Article
Closed access
ICIvan Carcamo-Orive
Ivan Carcamo-Orive
GHGabriel E Hoffman
Gabriel E Hoffman
PCPaige Cundiff
Paige Cundiff
NBNoam D Beckmann
Noam D Beckmann
SDSunita L D'Souza
Sunita L D'Souza
ILIhor Lemischka
Ihor Lemischka

27 May 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TCThe Colorectal Tumour Gene Identification (CORGI) Consortium
The Colorectal Tumour Gene Identification (CORGI) Consortium
MDMalcolm G Dunlop
Malcolm G Dunlop
TGThe Swedish Low-Risk Colorectal Cancer Study Group
The Swedish Low-Risk Colorectal Cancer Study Group
TGThe COIN Collaborative Group
The COIN Collaborative Group
SDSara E Dobbins
Sara E Dobbins
Richard HoulstonRichard Houlston
Richard Houlston

19 February 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
RJRoland Jäger
Roland Jäger
GMGabriele Migliorini
Gabriele Migliorini
MHMarc Henrion
Marc Henrion
RKRadhika Kandaswamy
Radhika Kandaswamy
HSHelen E. Speedy
Helen E. Speedy
Richard HoulstonRichard Houlston
Richard Houlston
Multiple regulatory elements distant from their targets on the linear genome can influence the expression of a single gene through chromatin looping. Chromosome conformation capture implemented in Hi-C allows for genome-wide agnostic characterization of chromatin contacts. However, detection of functional enhancer–promoter interactions is precluded by its effective resolution that is determined by both restriction fragmentation and sensitivity of the experiment. Here we develop a capture Hi-C (cHi-C) approach to allow an agnostic characterization of these physical interactions on a genome-wide scale. Single-nucleotide polymorphisms associated with complex diseases often reside within regulatory elements and exert effects through long-range regulation of gene expression. Applying this cHi-C approach to 14 colorectal cancer risk loci allows us to identify key long-range chromatin interactions in cis and trans involving these loci.